How CJC-1295 No-DAC Affects HDL Cholesterol

Growth hormone has complex effects on lipid metabolism that differ from the adverse lipid effects of AAS. The GH-axis generally supports a favourable lipid environment through several mechanisms:

1. Lipolysis and FFA clearance: GH promotes lipolysis, mobilising stored triglycerides from adipose tissue. While acute post-injection FFA elevation occurs during the GH pulse, the net effect on body composition (reduced visceral fat) over weeks to months is associated with improved lipid profiles, particularly reduced triglycerides and stable or improved HDL.
2. Hepatic lipid metabolism: GH influences hepatic lipoprotein production and clearance. GH deficiency is associated with increased LDL and triglycerides and decreased HDL. Restoring or amplifying GH signalling through GHRH analogs tends to reverse these dyslipidaemic patterns.
3. Tesamorelin evidence as the closest proxy: Falutz et al. (2010, PMID 20554713) conducted the largest controlled human trial of a GHRH analog for body composition, randomising 806 patients (HIV lipodystrophy) to daily tesamorelin 2 mg versus placebo for 26 to 52 weeks. Key lipid findings: total cholesterol to HDL ratio improved 7.2%, triglycerides fell 37 mg/dL at 26 weeks and 48 mg/dL at 52 weeks, and IGF-1 rose 108 ng/mL above placebo. HDL itself did not significantly change, but the ratio improvement reflects a favourable shift in the cholesterol environment.
4. CJC-1295 no-DAC extrapolation: No dedicated human trial has measured HDL specifically for the CJC-1295 no-DAC plus ipamorelin combination. The mechanistic prediction, supported by the tesamorelin data and the GH-deficiency reversal literature, is a neutral to modestly favourable effect on HDL and lipid ratios.
5. Contrast with AAS: Unlike testosterone, nandrolone, or trenbolone, which suppress HDL through hepatic lipase upregulation and SR-BI modulation, GH-axis activation does not activate the androgen-driven hepatic lipase pathway. The lipid mechanisms are entirely different.

Standard combined protocol (100 mcg CJC-1295 no-DAC + 200-300 mcg ipamorelin, 1-2 times daily):

• HDL: no significant change expected; possible mild improvement with long-term use
• Total cholesterol to HDL ratio: neutral to mildly improved; tesamorelin data showed 7.2% improvement at 52 weeks
• LDL: no significant change expected from GH-axis activation alone; triglycerides may modestly improve with long-term use
• Triglycerides: neutral to modestly reduced with long-term use; tesamorelin showed -37 to -48 mg/dL over 26 to 52 weeks

Important context: Users commonly stack CJC-1295 no-DAC plus ipamorelin with AAS, which have strongly adverse lipid effects (HDL suppression by 30 to 70%). The peptide components are not expected to counteract AAS-driven HDL suppression, but they do not add to it.

Timeline: Any lipid benefits from GH-axis activation are gradual and most apparent over months of consistent use, not within individual injection cycles.

Baseline: Full fasting lipid panel (total cholesterol, HDL, LDL, triglycerides, ideally ApoB) before starting. This establishes whether any AAS co-use has already compromised HDL.

During use:

• Lipid panel every 6 months on a long-term protocol as part of general cardiovascular monitoring
• If co-using AAS, frequency should reflect the lipid monitoring requirements of the AAS (often every 8 to 12 weeks on-cycle)
• Focus lipid monitoring on AAS-driven HDL suppression rather than the CJC-1295 no-DAC component

Recovery monitoring: After any AAS cycle, lipid panel at 8 to 12 weeks post-cycle to confirm HDL recovery. CJC-1295 no-DAC can be continued during the recovery period without lipid concern.

CJC-1295 no-DAC requires no lipid-specific management:

• No omega-3, niacin, or other lipid interventions are required specifically for CJC-1295 no-DAC
• If lipid monitoring shows HDL suppression while on a stack containing CJC-1295 no-DAC plus AAS, the AAS is the driver; address with AAS dose reduction, cycle shortening, increased cardiovascular exercise, and omega-3 supplementation

Using GH peptides during AAS recovery:

• Continuing ipamorelin and CJC-1295 no-DAC after an AAS cycle does not impede lipid recovery
• The neutral to favourable GH-axis lipid effects may provide a modest buffer against persistent lipid disruption, though this is mechanistic extrapolation rather than confirmed data

Maximising cardiovascular benefit from GH-axis activation:

• Regular cardiovascular exercise (150 to 200 minutes per week) synergises with GH-axis peptides for body composition improvement and independently supports HDL
• Visceral fat reduction from long-term GH peptide use is associated with improved lipid profiles; this is a realistic long-term benefit for users maintaining consistent protocols over 6 to 12 months